The aim of our review is to uncover which real world datasets, based on patient / disease based registries, exist in Europe regarding breast cancer. We also aim to understand how these differ in the ability to conduct outcomes research using the available data.
Blog
The aim of our review is to uncover which real world datasets, based on patient / disease based registries, exist in Europe regarding heart failure. We also aim to understand how these differ in the ability to conduct outcomes research using the available data.
This is a summary of the pilot study regarding the development of a value-based monitoring platform for breast cancer care in Sweden.
Initial analysis of data
We have started several projects that aim to understand which patient / disease registries have the ability to be used in outcomes research.
Electronic health records and clinical cardiovascular quality registries provide opportunities for pragmatic clinical trial (PCT) and registry-based prospective randomized clinical trials (RRCTs).
The randomized clinical trial (RCT) is a powerful tools for clinical researchers, which evaluates the effectiveness of new (or established) treatments while accounting for the effects of unmeasured
Personalized medicine (or precision or stratified medicine as new terms introduced nowadays) is recently defined as: “Treatments targeted to the needs of individual patients on the basis of genetic
HTA plays an increasingly important role for Medical Device and IVD companies. Below is a summary of the HTA Dynamics during 2016, followed by the same data for 2015.
A common limitation encountered by researchers wishing to analyse the relative effectiveness or safety of a drug, device or other medical intervention using real world observational data i
This blog provides summary on what is known about initial §137h NUB-related submission by Bioventrix, Holaira and Haifu.

